Pfizer Will Review Cholesterol Drug Category To Gauge Longevity Of Slowdown
Executive Summary
Pfizer's annual financial analysis will include a review of the cholesterol-lowering drug market to determine if a more than 50% drop in new prescription growth rates in the third quarter is a short-term or long-term effect, CEO Hank McKinnell said
You may also be interested in...
Simvastatin switch savings
Express Scripts member plans have saved $230 million on cholesterol-fighting drugs through increased generic utilization since January 2006, the pharmacy benefit manager reports April 26. The PBM aggressively promoted therapeutic switching from Pfizer's Lipitor (atorvastatin) to Merck's Zocor (simvastatin) prior to the introduction of generic simvastatin (1"The Pink Sheet" Oct. 24, 2005, p. 19). With the launch of generic simvastatin and generic pravastatin (Bristol-Myers Squibb's Pravachol) in 2006, "use of generic cholesterol-fighting drugs has increased from eight percent to 44 percent," Express Scripts says...
Simvastatin switch savings
Express Scripts member plans have saved $230 million on cholesterol-fighting drugs through increased generic utilization since January 2006, the pharmacy benefit manager reports April 26. The PBM aggressively promoted therapeutic switching from Pfizer's Lipitor (atorvastatin) to Merck's Zocor (simvastatin) prior to the introduction of generic simvastatin (1"The Pink Sheet" Oct. 24, 2005, p. 19). With the launch of generic simvastatin and generic pravastatin (Bristol-Myers Squibb's Pravachol) in 2006, "use of generic cholesterol-fighting drugs has increased from eight percent to 44 percent," Express Scripts says...
WellPoint Offers Simvastatin Free Trial; Preferred Brand Lipitor Left In Dust?
WellPoint beneficiaries will be able to receive up to four months of generic simvastatin as an incentive to switch from a branded cholesterol-lowering agent